Evidence map›Paper›PMID 19538983›Full record

ArticleToxicology and applied pharmacology2009

Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions.

Olga L Valenzuela, Zuzana Drobná, Erika Hernández-Castellanos, Luz C Sánchez-Peña, Gonzalo G García-Vargas, Víctor H Borja-Aburto, Miroslav Stýblo, Luz M Del Razo

Abstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 108 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Arsenic Impairs Wound Healing Processes in Dermal Fibroblasts and Mice.International journal of molecular sciences · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Factors Affecting Arsenic Methylation in Contaminated Italian Areas.International journal of environmental research and public health · 2020
    Article
  11. Article
  12. Circulating miRNAs Associated with Arsenic Exposure.Environmental science & technology · 2018
    Article
  13. Article
  14. Article
  15. Urinary Arsenic in Human Samples from Areas Characterized by Natural or Anthropogenic Pollution in Italy.International journal of environmental research and public health · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Olga L ValenzuelaToxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politecnico Nacional (Cinvestav-IPN), Av. IPN 2508, San Pedro Zacatenco, México D. F., C. P. 07360, Mexico.
Zuzana Drobná
Erika Hernández-Castellanos
Luz C Sánchez-Peña
Gonzalo G García-Vargas
Víctor H Borja-Aburto
Miroslav Stýblo
Luz M Del Razo
Center for Research and Advanced Studies of the National Polytechnic Institute · MXUniversity of North Carolina at Chapel Hill · USInstituto Politécnico Nacional · MXMexican Social Security Institute · MXUniversidad Juárez del Estado de Durango · MX

Funding

Metabolism and Toxicity of Arsenic in the Human LiverR01ES010845 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI STYBLO, MIROSLAV · 2003 to 2010
$2.3M
NIEHS NIH HHS R01 ES010845
6 · The paper itself

Abstract

Exposure to naturally occurring inorganic arsenic (iAs), primarily from contaminated drinking water, is considered one of the top environmental health threats worldwide. Arsenic (+3 oxidation state) methyltransferase (AS3MT) is the key enzyme in the biotransformation pathway of iAs. AS3MT catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to trivalent arsenicals, resulting in the production of methylated (MAs) and dimethylated arsenicals (DMAs). MAs is a susceptibility factor for iAs-induced toxicity. In this study, we evaluated the association of the polymorphism in AS3MT gene with iAs metabolism and with the presence of arsenic (As) premalignant skin lesions. This is a case-control study of 71 cases with skin lesions and 51 controls without skin lesions recruited from a iAs endemic area in Mexico. We measured urinary As metabolites, differentiating the trivalent and pentavalent arsenical species, using the hydride generation atomic absorption spectrometry. In addition, the study subjects were genotyped to analyze three single nucleotide polymorphisms (SNPs), A-477G, T14458C (nonsynonymus SNP; Met287Thr), and T35587C, in the AS3MT gene. We compared the frequencies of the AS3MT alleles, genotypes, and haplotypes in individuals with and without skin lesions. Marginal differences in the frequencies of the Met287Thr genotype were identified between individuals with and without premalignant skin lesions (p=0.055): individuals carrying the C (TC+CC) allele (Thr) were at risk [odds ratio=4.28; 95% confidence interval (1.0-18.5)]. Also, individuals with C allele of Met287Thr displayed greater percentage of MAs in urine and decrease in the percentage of DMAs. These findings indicate that Met287Thr influences the susceptibility to premalignant As skin lesions and might be at increased risk for other adverse health effects of iAs exposure.

Indexed as

Polymorphism, Single NucleotideAdolescentAdultArsenicCase-Control StudiesCross-Sectional StudiesDNAEnvironmental ExposureFemaleGene FrequencyGenotypeHumansMaleMethyltransferasesMexicoMiddle AgedArsenicAS3MT protein, humanDNAMethyltransferasesWater Pollutants, Chemical

Identifiers

PMID19538983
PMCPMC2910909
OpenAlexW2124353746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.